The No Surprises Act (NSA), a landmark piece of legislation affecting the healthcare industry, has been in effect since January 2022. Despite its intent to mitigate the financial strain of unexpected medical bills for patients, the act has continuously faced litigation initiated by healthcare providers since its implementation.
Both state and federal agencies are scrutinizing surprise medical billing and consumer protection regulations pertaining to certain stipulations of the NSA. This flurry of activities has stirred dialogues around the current condition of NSA lawsuits, various oversight initiatives, as well as rulemaking and guidance as Q4 2023 is now upon us.
Healthcare providers will likely continue to navigate through developing enforcement trends, agency directives, as well as upcoming rulemaking that could have a substantial impact on their operations. The complex legal landscape that the NSA has formed presents various challenges but also bodes potential scenarios for adaptation and progress.
McDermott Will & Emery have given their perspective on these evolution trends and propose what the healthcare industry could expect going forward. For more detailed insights, you may refer to their complete findings in the comprehensive report attached in the link.